Susquehanna International Group
SLXNW

Susquehanna International Group’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Susquehanna International Group’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-220,053
Closed -$7.75K – 13909
2025
Q3 		$7.75K Buy
220,053
+69,071
+46% +$2.42K ﹤0.01% 12114
2025
Q2 		$5.75K Buy
150,982
+99,181
+191% +$5.26K ﹤0.01% 12435
2025
Q1 		$3.63K Buy
+51,801
New +$3.15K ﹤0.01% 12274
2024
Q4 		– Sell
-34,577
Closed -$1.1K – 13450
2024
Q3 		$1.1K Buy
+34,577
New +$2K ﹤0.01% 11804

Other funds holding SLXNW

OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return

Susquehanna International Group's SLXNW Position: Q4 2025 in Review

Susquehanna International Group sold out of Silexion Therapeutics Warrant (SLXNW) in Q4 2025, closing a stake of 220,053 shares — an estimated $7.75K sold.

Susquehanna International Group first reported a position in SLXNW in Q3 2024 and held it in 4 quarters. The position peaked at $7.75K in Q3 2025. 22 funds tracked by Wall St. Rank hold SLXNW as of Q4 2025.

  • Susquehanna International Group reported no remaining Silexion Therapeutics Warrant position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 220,053 Silexion Therapeutics Warrant shares in Q4 2025, an estimated $7.75K.
  • Susquehanna International Group first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 4 quarters.
  • Susquehanna International Group's Silexion Therapeutics Warrant position peaked at $7.75K in Q3 2025.
  • 22 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.